Reviews - 3muk mentioned but not cited (1)
- Insights into newly discovered marks and readers of epigenetic information. Andrews FH, Strahl BD, Kutateladze TG. Nat Chem Biol 12 662-668 (2016)
Articles - 3muk mentioned but not cited (1)
- Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4. Olp MD, Zhu N, Smith BC. Biochemistry 56 5485-5495 (2017)
Reviews citing this publication (24)
- Metabolic regulation of gene expression through histone acylations. Sabari BR, Zhang D, Allis CD, Zhao Y. Nat Rev Mol Cell Biol 18 90-101 (2017)
- Interpreting the language of histone and DNA modifications. Rothbart SB, Strahl BD. Biochim Biophys Acta 1839 627-643 (2014)
- Bromodomains as therapeutic targets. Muller S, Filippakopoulos P, Knapp S. Expert Rev Mol Med 13 e29 (2011)
- The bromodomain interaction module. Filippakopoulos P, Knapp S. FEBS Lett 586 2692-2704 (2012)
- Protein lysine acylation and cysteine succination by intermediates of energy metabolism. Lin H, Su X, He B. ACS Chem Biol 7 947-960 (2012)
- A comprehensive view of the epigenetic landscape. Part II: Histone post-translational modification, nucleosome level, and chromatin regulation by ncRNAs. Sadakierska-Chudy A, Filip M. Neurotox Res 27 172-197 (2015)
- Compartmentalised acyl-CoA metabolism and roles in chromatin regulation. Trefely S, Lovell CD, Snyder NW, Wellen KE. Mol Metab 38 100941 (2020)
- Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. Wadhwa E, Nicolaides T. Cureus 8 e620 (2016)
- Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases. Padmanabhan B, Mathur S, Manjula R, Tripathi S. J Biosci 41 295-311 (2016)
- Epigenome-modifying tools in asthma. Brook PO, Perry MM, Adcock IM, Durham AL. Epigenomics 7 1017-1032 (2015)
- Functional Roles of Bromodomain Proteins in Cancer. Boyson SP, Gao C, Quinn K, Boyd J, Paculova H, Frietze S, Glass KC. Cancers (Basel) 13 3606 (2021)
- Selective targeting of epigenetic reader domains. Greschik H, Schüle R, Günther T. Expert Opin Drug Discov 12 449-463 (2017)
- An Expanding Repertoire of Protein Acylations. Xu Y, Shi Z, Bao L. Mol Cell Proteomics 21 100193 (2022)
- Binding Mode of Acetylated Histones to Bromodomains: Variations on a Common Motif. Marchand JR, Caflisch A. ChemMedChem 10 1327-1333 (2015)
- Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential. Vu LP, Luciani L, Nimer SD. Int J Hematol 97 198-209 (2013)
- Oncometabolites drive tumorigenesis by enhancing protein acylation: from chromosomal remodelling to nonhistone modification. Fu Y, Yu J, Li F, Ge S. J Exp Clin Cancer Res 41 144 (2022)
- Mitochondrial cytochrome c shot towards histone chaperone condensates in the nucleus. González-Arzola K, Guerra-Castellano A, Rivero-Rodríguez F, Casado-Combreras MÁ, Pérez-Mejías G, Díaz-Quintana A, Díaz-Moreno I, De la Rosa MA. FEBS Open Bio 11 2418-2440 (2021)
- Chemogenomics for drug discovery: clinical molecules from open access chemical probes. Quinlan RBA, Brennan PE. RSC Chem Biol 2 759-795 (2021)
- Tumor-Promoting ATAD2 and Its Preclinical Challenges. Liu H, Wen Q, Yan S, Zeng W, Zou Y, Liu Q, Zhang G, Zou J, Zou X. Biomolecules 12 1040 (2022)
- Fragment-Based Drug Discovery in the Bromodomain and Extra-Terminal Domain Family. Radwan M, Serya R. Arch Pharm (Weinheim) 350 (2017)
- Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN. Shi X, Wang Y, Zhang L, Zhao W, Dai X, Yang YG, Zhang X. Front Cell Dev Biol 10 1021820 (2022)
- Catching Nucleosome by Its Decorated Tails Determines Its Functional States. Sehrawat P, Shobhawat R, Kumar A. Front Genet 13 903923 (2022)
- Functions and mechanisms of protein lysine butyrylation (Kbu): Therapeutic implications in human diseases. Xue Q, Yang Y, Li H, Li X, Zou L, Li T, Ma H, Qi H, Wang J, Yu T. Genes Dis 10 2479-2490 (2023)
- Post-Translational Modifications by Lipid Metabolites during the DNA Damage Response and Their Role in Cancer. Zhu G, Zheng X, Wang Z, Xu X. Biomolecules 12 1655 (2022)
Articles citing this publication (15)
- Molecular Coupling of Histone Crotonylation and Active Transcription by AF9 YEATS Domain. Li Y, Sabari BR, Panchenko T, Wen H, Zhao D, Guan H, Wan L, Huang H, Tang Z, Zhao Y, Roeder RG, Shi X, Allis CD, Li H. Mol Cell 62 181-193 (2016)
- Dynamic Competing Histone H4 K5K8 Acetylation and Butyrylation Are Hallmarks of Highly Active Gene Promoters. Goudarzi A, Zhang D, Huang H, Barral S, Kwon OK, Qi S, Tang Z, Buchou T, Vitte AL, He T, Cheng Z, Montellier E, Gaucher J, Curtet S, Debernardi A, Charbonnier G, Puthier D, Petosa C, Panne D, Rousseaux S, Roeder RG, Zhao Y, Khochbin S. Mol Cell 62 169-180 (2016)
- Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. Itzen F, Greifenberg AK, Bösken CA, Geyer M. Nucleic Acids Res 42 7577-7590 (2014)
- Cell signaling, post-translational protein modifications and NMR spectroscopy. Theillet FX, Smet-Nocca C, Liokatis S, Thongwichian R, Kosten J, Yoon MK, Kriwacki RW, Landrieu I, Lippens G, Selenko P. J Biomol NMR 54 217-236 (2012)
- Histone propionylation is a mark of active chromatin. Kebede AF, Nieborak A, Shahidian LZ, Le Gras S, Richter F, Gómez DA, Baltissen MP, Meszaros G, Magliarelli HF, Taudt A, Margueron R, Colomé-Tatché M, Ricci R, Daujat S, Vermeulen M, Mittler G, Schneider R. Nat Struct Mol Biol 24 1048-1056 (2017)
- Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases. Wang Y, Stowe RL, Pinello CE, Tian G, Madoux F, Li D, Zhao LY, Li JL, Wang Y, Wang Y, Ma H, Hodder P, Roush WR, Liao D. Chem Biol 22 273-284 (2015)
- Molecular design, functional characterization and structural basis of a protein inhibitor against the HIV-1 pathogenicity factor Nef. Breuer S, Schievink SI, Schulte A, Blankenfeldt W, Fackler OT, Geyer M. PLoS One 6 e20033 (2011)
- Replica-Exchange and Standard State Binding Free Energies with Grand Canonical Monte Carlo. Ross GA, Bruce Macdonald HE, Cave-Ayland C, Cabedo Martinez AI, Essex JW. J Chem Theory Comput 13 6373-6381 (2017)
- Comparative analysis of histone H3 and H4 post-translational modifications of esophageal squamous cell carcinoma with different invasive capabilities. Zhang K, Li L, Zhu M, Wang G, Xie J, Zhao Y, Fan E, Xu L, Li E. J Proteomics 112 180-189 (2015)
- Histone Adduction and Its Functional Impact on Epigenetics. Galligan JJ, Marnett LJ. Chem Res Toxicol 30 376-387 (2017)
- Multi-omic analysis of gametogenesis reveals a novel signature at the promoters and distal enhancers of active genes. Crespo M, Damont A, Blanco M, Lastrucci E, Kennani SE, Ialy-Radio C, Khattabi LE, Terrier S, Louwagie M, Kieffer-Jaquinod S, Hesse AM, Bruley C, Chantalat S, Govin J, Fenaille F, Battail C, Cocquet J, Pflieger D. Nucleic Acids Res 48 4115-4138 (2020)
- Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer. Slavish PJ, Chi L, Yun MK, Tsurkan L, Martinez NE, Jonchere B, Chai SC, Connelly M, Waddell MB, Das S, Neale G, Li Z, Shadrick WR, Olsen RR, Freeman KW, Low JA, Price JE, Young BM, Bharatham N, Boyd VA, Yang J, Lee RE, Morfouace M, Roussel MF, Chen T, Savic D, Guy RK, White SW, Shelat AA, Potter PM. Cancer Res 80 3507-3518 (2020)
- Histone acylation marks respond to metabolic perturbations and enable cellular adaptation. Jo C, Park S, Oh S, Choi J, Kim EK, Youn HD, Cho EJ. Exp Mol Med 52 2005-2019 (2020)
- Characterizing crosstalk in epigenetic signaling to understand disease physiology. Lempiäinen JK, Garcia BA. Biochem J 480 57-85 (2023)
- FGFR2-BRD4 Axis Regulates Transcriptional Networks of Histone 3 Modification and Synergy Between Its Inhibitors and PD-1/PD-L1 in a TNBC Mouse Model. Lei JH, Zhang L, Wang Z, Peltier R, Xie Y, Chen G, Lin S, Miao K, Deng CX, Sun H. Front Immunol 13 861221 (2022)